1. A prospective randomized study of Chop versus Chop plus Alpha-2B interferon in patients with Intermediate and High Grade non-Hodgkin's lymphoma: The International Oncology Study Group NHL1 study
- Author
-
Soon Keng Cheong, Villalon Ah, Chen Pm, Hamdy A. Azim, Sang We Kim, Suharti C, Poovalingam Vp, Francis J. Giles, Supindiman I, Tee Gy, Hamza R, Song Hs, Lei Ki, Hamdi Akan, Ruff P, Wickham Nr, Khalid Hm, Muthalib A, Yalcin A, Burhan Ferhanoglu, Kumar R, Sagar Tg, Saengsuree Jootar, Wichai Prayoonwiwat, Reksodiputro Ah, Zeba Aziz, P P Bapsy, Buyukkececi F, Wong Je, Boonsom Chaimongkol, Haluk Koç, Jianqin Shan, Patel M, Ismet Aydogdu, Schwarer Ap, Kim Sy, Rana F, Intragumtornchai T, Lalit Kumar, Suresh H. Advani, Cheolwon Suh, Arnuparp Lekhakula, and Thamprasit T
- Subjects
Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Vincristine ,Working Formulation ,Alpha interferon ,Interferon alpha-2 ,CHOP ,immune system diseases ,hemic and lymphatic diseases ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Medicine ,Prospective Studies ,Cyclophosphamide ,Survival rate ,business.industry ,Lymphoma, Non-Hodgkin ,Interferon-alpha ,Hematology ,Middle Aged ,medicine.disease ,Recombinant Proteins ,Lymphoma ,Non-Hodgkin's lymphoma ,Survival Rate ,Regimen ,Treatment Outcome ,Doxorubicin ,Prednisone ,Female ,business ,medicine.drug - Abstract
The addition of a brief alpha interferon regimen to each CHOP induction cycle, plus one year of alpha interferon thrice weekly maintenance therapy, has no early effect on response rates or survival in patients with Intermediate or High grade cell NHL.The CHOP (Cyclophosphamide, Adriamycin. Vincristine, Prednisone) regimen is the most widely used first-line therapy for patients with Intermediate or High Grade (IG/HG) non-Hodgkin's lymphoma (NHL). Alpha 2b interferon (INF) enhances response rates and improves survival in low-grade NHL. The International Oncology Study Group (IOSG) conducted a prospective randomized study comparing CHOP alone or combined with INF in patients with IG/HG-NHL. The primary study aim was to compare the objective response rates in these patient cohorts.Patients with a confirmed diagnosis of measurable NHL of International Working Formulation (IWF) groups D to H histology were randomized to receive CHOP alone or CHOP with 5Mu INF s.c. for 5 days on days 22 to 26 of each 28 day cycle with INF 5 million units (Mu) given three times per week subcutaneously for 52 weeks in those patients who responded to CHOP plus INF.The overall response rates were equivalent in both groups: CHOP alone (214 patients) 81% (complete 55%, partial 26%); CHOP plus INF (221 patients) 80% (complete 54%, partial 26%). At 36 months, the actuarial survival rate was equivalent in both groups.There is no apparent early advantage in terms of response or survival conferred by adding the study INF regimen to CHOP therapy for patients with IG/HG-NHL.